Yes, It Is Worth It: Consider Participant Experiences in the Design of Future Trials.
Clinical cancer prevention and interception trials target high-risk populations and require agents with favorable risk-to-benefit ratios. Participant experiences are crucial in trial design, as highlighted in this issue of Cancer Prevention Research by Zahrieh and colleagues, which applied the "Was It Worth It?" questionnaire to evaluate participants' experiences in cancer chemoprevention trials. This study is the first examination of satisfaction in early-phase chemoprevention trials for high-risk individuals. This timely study underscores the need to assess and integrate participant and advocate feedback in completed, ongoing, and future trials. This spotlight commentary emphasizes the importance of participant experiences in enhancing trial designs for cancer prevention and interception. See related article by Zahrieh et al., p. 11.